Thijs Hendrikx

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

Philip J. Mease, Stephen Hall, Oliver FitzGerald et al. · New England Journal of Medicine · 2017 · 536 citations

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

Dafna D. Gladman, William F. C. Rigby, Valderílio Feijó Azevedo et al. · New England Journal of Medicine · 2017 · 494 citations · Full text

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

Désirée van der Heijde, Atul Deodhar, James Cheng‐Chung Wei et al. · Annals of the Rheumatic Diseases · 2017 · 361 citations · Full text

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler et al. · The Lancet · 2018 · 251 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +7

End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells

Thijs Hendrikx, Evelien A. F. J. van Gurp, Wendy M. Mol et al. · Nephrology Dialysis Transplantation · 2009 · 105 citations · Full text